PAVmed
Medical Devices
New York, New York

Overall Rank: 285
Category: Medical Devices
Category Rank: 48

Profile

PAVmed is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.


Backed by a strong track record of entrepreneurship, our leadership team has the clinical expertise, commercial acumen and proven business model to identify, innovate, and commercialize high-margin products in attractive markets with far less capital and greater speed to market than typical medical device companies.


Visit: www.pavmed.com


Key Products

ESOCHECK – CELL COLLECTION DEVICE is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy. The sampled cells can then be subjected to any commercially available diagnostic test.


ESOGUARD – Esophageal DNA test is a laboratory developed test that have been proven to show over 90% specificity and 90% sensitivity in identifying biomarkers for Barrett’s Esophagus.


The assay examines individual DNA molecules for the presence or absence of cytosine methylation at 31 different genomic locations.


CarpX is a minimally invasive device designed to treat carpal tunnel syndrome, allowing the physician to relieve the compression of the median nerve without a traditional surgical incision. CarpX incorporates a balloon catheter with bipolar radio-frequency cutting electrodes. The device is advanced over a wire and positioned in the carpal tunnel under ultrasonic guidance.


PortIO


The intraosseous route provides a means for infusing fluids, medications, and other substances directly into the bone marrow cavity which communicates with the central venous circulation via nutrient and emissary veins. This route, which has been used for decades, is well established and has been shown to bioequivalent to the intravenous route. PortIO is a novel, implantable, intraosseous vascular access device, which, unlike existing long-term vascular access devices, does not have a component residing in a vein


DISAPPEAR


In 2016, they entered into a licensing agreement with a group of leading academic institutions, which provided them with an exclusive worldwide license to develop and commercialize antimicrobial resorbable ear tubes based on a proprietary aqueous silk technology conceived and developed at these institutions. They believe DisappEAR ear tubes will eliminate the need for a second general anesthesia procedure to remove retained or dislodged tubes in most patients. In addition, its antimicrobial quality will eliminate the difficult-to-administer post-procedure antibiotic ear drop regimen.


Key Executives

Lishan Aklog, MD, Chairman & Chief Executive Officer


Lishan Aklog, M.D. has been the Company’s Chairman and Chief Executive Officer since its inception. Dr. Aklog has also served as a member of the board of directors of HCFP, Inc., and as a co-founding Partner of both Pavilion Holdings Group (“PHG”), and Pavilion Medical Innovations (“PMI”). Dr. Aklog previously served as Chairman and Chief Technology Officer of Vortex Medical Inc.


Dr. Aklog has been a consultant to Biomet Inc., now Zimmer Biomet since 2009. He previously served as a consultant to AngioDynamics, Edward Lifesciences Corp, On-X Life Technologies Inc.and Atricure Inc. Dr. Aklog also previously served on the Scientific Advisory Boards of numerous leading medical device companies, including Medtronic, St. Jude Medical, Guidant Cardiac Surgery (now, Maquet Cardiovascular) and Cardiovations (then, a division of Johnson & Johnson).


Dennis McGrath, President & Chief Financial Officer


Dennis M. McGrath has served as the Company’s Executive Vice President and Chief Financial Officer since March 2017.


Previously, Mr. McGrath served in several senior level positions of PhotoMedex, Inc. Prior to PhotoMedex’s reverse merger with Radiancy, Inc in December 2011, he also served as Chief Executive Officer and served as Vice President of Finance and Chief Financial Officer.


During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. In addition to continuing as a director of PhotoMedex, he serves as the audit chair and a director of several medical device companies, including DarioHealth Corp., Noninvasive Medical Technologies, Inc. and Cagent Vascular, LLC, and as an advisor to the board of an orphan drug company, Palvella Therapeutics, LLC. Formerly, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. He also serves on the Board of Trustees for Manor College and the Board of Visitors for Taylor University.


Brian DeGuzman, MD, Chief Medical Officer


Dr. DeGuzman has served as PAVmed’s Chief Medical Officer since October 2014 and served as a Director. Dr. deGuzman has previously served as a co-founding Partner of Pavilion Holdings Group (“PHG”), and Pavilion Medical Innovations (“PMI”), since 2007.


Dr. deGuzman has been President and Chief Executive Officer of Kaleidoscope Medical since its founding in February 2013 and has also served as a Senior Advisor to PMI portfolio companies Saphena Medical and Cruzar Medsystems. Dr. deGuzman served as Chief Medical Officer of Vortex Medica and has also been a consultant to Biomet, Atricure, and on the Revascularization Scientific Advisory Board of Maquet Cardiovascular since 2006.


Dr. deGuzman received his general surgical training at the University of Connecticut/Hartford Hospital, was a Research Fellow at Harvard Medical School’s Cardiac Surgery Research Laboratory, and received his cardiothoracic surgical training at Brigham and Women’s Hospital and Boston Children’s Hospital. Dr. deGuzman was recognized as a Top Doctor in Cardiovascular Surgery by Boston Magazine. Dr. deGuzman received his B.S. in Biology from Boston College and his M.D. from Georgetown University School of Medicine.


Shaun ONeil, MBA, EVP & Chief Operating Officer


Shaun M. O’Neil has served as the Company’s Chief Commercial Officer since July 2018.


As PAVmed’s Chief Commercial Officer he is responsible for the planning and execution of both sales and marketing activities for the U.S., Europe, South America, and Asia. His responsibilities include the development of PAVmed’s strategic partnerships, distribution channels, creation of growth strategies and successful business solutions for branding and positioning of the product lines as well as organize, develop, and grow the sales organization. Shaun works closely with, surgeons, clinicians, medical device manufacturers and distributors, technology business managers, as well as research and development partners around the globe.


Since 2011, Mr. O’Neil has held various sales and marketing leadership positions with AngioDynamics. Prior to AngioDynamics, he served in various sales, marketing and engineering roles at Aycan Medical Systems.


Mr. O’Neil received a B.S. in Business Administration with a focus in management information systems from Alfred University and an M.B.A. from the Rochester Institute of Technology.